© 2022 MJH Life Sciences™ and Contemporary Pediatrics. All rights reserved.
Drug Pipeline News
Regeneron reports evinacumab phase 3 results for children 5 to 11 years old with HoFH
May 23, 2022
Evinacumab phase 3 results show a 48% LDL-C reduction in children with homozygous familial hypercholesterolemia.
Must-read news from the week of May 16
May 20, 2022
A look at what the Contemporary Pediatrics® team covered this week.
Donna Hallas discusses the Pfizer-BioNTech vaccine booster for children 5 to 11 years old
May 19, 2022
Contemporary Pediatrics® Editorial Advisory Board member Donna Hallas shares her thoughts on the recent authorization of a Pfizer-BioNTech COVID-19 booster shot for children 5-11 years old.
FDA Authorizes Pfizer-BioNTech Booster Shot for Children Ages 5 to 11
May 17, 2022
Children may receive a single booster shot at least 5 months after completing their initial Pfizer-BioNTech 2-dose series.
Pfizer/BioNTech show high immune response in a booster dose against Omicron in clinical trial for children 5-11 years
April 15, 2022
Pfizer/BioNTech announce positive results for a third dose of their COVID-19 vaccine for children
Dr. Amy Paller discusses long-term safety and efficacy of ixekizumab in kids
April 05, 2022
Dr. Paller discusses the findings of the clinical trial examining the long-term effects of ixekizumab for treating psoriasis in children.
Considerations for Moderna's move to get an EUA for the COVID-19 vaccine in young kids
March 25, 2022
Editorial board member Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN, discusses the recently release topline data, the potential timeline, and what potential stumbling blocks could be.
How to talk with parents about the recent Pfizer/BioNTech news for the youngest kids
February 24, 2022
Editor-in-chief Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, discusses how to help parents who are worried or nervous about the delay in the expansion of the Pfizer/BioNTech vaccine to children aged 6 months to younger than 4 years.
Novavax pediatric COVID-19 vaccine trial yields positive results
February 14, 2022
The NVX-CoV2373 vaccine was evaluated in adolescents aged 12 to 17 years.
FDA grants Priority Review to Dupixent® for kids 6 months to 5 years
February 10, 2022
The US Food and Drug Administration has given Priority Review to the supplemental Biologics License Application for the use of Dupixent® as an add-on maintenance treatment for moderate-to-severe dermatitis in children aged 6 months to 5 years.